Mycobacterium tuberculosis Cluster with Developing Drug Resistance, New York, New York, USA, 2003–2009
Bianca R. Perri , Douglas Proops, Patrick K. Moonan, Sonal S. Munsiff, Barry N. Kreiswirth, Natalia Kurepina, Christopher Goranson, and Shama D. Ahuja
Author affiliations: Author affiliations: New York City Department of Health and Mental Hygiene, New York, New York, USA (B.R. Perri, D. Proops, S.S. Munsiff, C. Goranson, S.D. Ahuja); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (B.R. Perri, P.K. Moonan, S.S. Munsiff); Public Health Research Institute Tuberculosis Center, Newark, New Jersey, USA (B.N. Kreiswirth, N. Kurepina)
Figure 3. IS6110 restriction fragment length polymorphism patterns for tuberculosis patients, New York, New York, USA, 2003–2009. Left lane, molecular mass ladder; lane A, n = 48; lane B, n = 1; lane C, n = 1; lane D, n = 4. Spoligotype results (octal code designation) were 777777774020771 for 54 patients. Twelve-loci mycobacterial interspersed repetitive-unit variable-number tandem repeat results were 225313153321 for 53 patients and 2253131–3321 for 1 patient; the dash indicates that there was no peak at this locus for this 1 patient, and the patient with this isolate met the original cluster case definition.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.